Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DML8MSC)

Drug Name

CL 385319 Drug Info

Synonyms

CHEMBL2088468; cl-385319

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Influenza Hemagglutinin (Influ HA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arbidol	DMOQK8Z	Virus infection	1A24-1D9Z	Approved	[2]
CR8020	DMQ47U6	Influenza virus infection	1E30-1E32	Phase 2	[3]
RG7745	DMK5PYS	Infectious disease	1A00-CA43.1	Phase 2	[4]
VIS410	DM1G6ME	Influenza A virus infection	1E30	Phase 2	[5]
ND-1.1	DMVQAEK	Influenza virus infection	1E30-1E32	Phase 1	[6]
VGX-3400	DMGMEH7	Influenza A virus H5N1 infection	1E30	Phase 1	[7]
A/Anhui/05	DMGJ7A4	Influenza virus infection	1E30-1E32	Phase 1	[8]
VIR-2482	DM6LQIU	Influenza A virus infection	1E30	Phase 1	[9]
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[10]
BMY-27709	DMAMYWL	Discovery agent	N.A.	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Influenza Hemagglutinin (Influ HA)	TTF4CAM	HEMA_I34A1	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17736-41.
2	Pharmacokinetic properties and bioequivalence of two formulations of arbidol: an open-label, single-dose, randomized-sequence, two-period crossover study in healthy Chinese male volunteers. Clin Ther. 2009 Apr;31(4):784-92.
3	Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin. J Virol. 2014 Dec;88(23):13580-92.
4	Clinical pipeline report, company report or official report of Roche.
5	Clinical pipeline report, company report or official report of Visterra.
6	An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models. Clin Vaccine Immunol. 2013 Jan;20(1):85-94.
7	Clinical pipeline report, company report or official report of Inovio Pharmaceuticals.
8	A Human Antibody Recognizing a Conserved Epitope of H5 Hemagglutinin Broadly Neutralizes Highly Pathogenic Avian Influenza H5N1 Viruses. J Virol. 2012 March; 86(6): 2978-2989.
9	Clinical pipeline report, company report or official report of Vir Biotechnology.
10	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.